Table 2 Open in new tab Univariate and...

	Univariate	Multivariate
Age >75 ≤75	91.2 94.6	80.4–96.3 92.2–96.3	0.78
PS ≤1 >1	94.6 94.2	87.7–97.7 91.6–96.1	0.46
NCCN Low-intermediate risk High risk	90.1 88.6	86.4–93.8 81.3–93.4	0.015	1.05	0.46–2.40	0.90
T stage T1–T2 T3–T4	95.8 86.6	93.4–97.4 78.3–92.0	0.010	1.24	0.56–2.71	0.59
Gleason score ≤8 >8	96.0 84.1	93.7–97.5 74.3–90.6	0.0002	1.52	0.60–3.87	0.35
PSA (ng/ml) ≤50 >50	95.1 77.9	92.9–96.7 58.5–89.8	0.0043	1.24	0.39–3.98	0.72
Radiation therapy PBT IMRT	95.1 89.9	92.7–96.7 80.8–95.0	0.027	2.20	1.13–4.33	0.021
Durations of ADT (month) ≥24 <24	92.7 94.9	87.2–95.9 92.1–96.7	0.45
Nodal risk (%) ≥40 <40	96.1 78.3	94.0–97.6 96.0–87.0	<0.0001	3.87	1.33–11.2	0.013
Private insurance coverage for PBT With coverage Without coverage	94.9 94.0	90.1–97.4 91.0–96.0	0.94
Heart disease With Without	93.6 94.3	85.5–73.3 91.3–96.2	0.27
Brain stroke With Without	92.9 94.4	75.6–98.2 92.0–96.1	0.66
Hypertension With Without	96.0 93.2	92.4–97.9 89.9–95.5	0.54
Diabetes mellitus With Without	95.5 94.1	86.9–98.5 91.5–95.9	0.69
Smoking With Without	97.0 92.7	93.6–98.7 89.4–95.0	0.10
Alcoholic history With Without	95.2 93.6	91.7–97.2 90.0–96.0	0.88

Univariate

Multivariate

Parameter

bRFS at 7 years (%)

95% CI

P-value

95% CI

P-value

Age
>75
≤75

91.2
94.6

80.4–96.3
92.2–96.3

0.78

PS
≤1
>1

94.6
94.2

87.7–97.7
91.6–96.1

0.46

NCCN
Low-intermediate risk
High risk

90.1
88.6

86.4–93.8
81.3–93.4

0.015

1.05

0.46–2.40

0.90

T stage
T1–T2
T3–T4

95.8
86.6

93.4–97.4
78.3–92.0

0.010

1.24

0.56–2.71

0.59

Gleason score
≤8
>8

96.0
84.1

93.7–97.5
74.3–90.6

0.0002

1.52

0.60–3.87

0.35

PSA (ng/ml)
≤50
>50

95.1
77.9

92.9–96.7
58.5–89.8

0.0043

1.24

0.39–3.98

0.72

Radiation therapy
PBT
IMRT

95.1
89.9

92.7–96.7
80.8–95.0

0.027

2.20

1.13–4.33

0.021

Durations of ADT (month)
≥24
<24

92.7
94.9

87.2–95.9
92.1–96.7

0.45

Nodal risk (%)
≥40
<40

96.1
78.3

94.0–97.6
96.0–87.0

<0.0001

3.87

1.33–11.2

0.013

Private insurance coverage for PBT
With coverage
Without coverage

94.9
94.0

90.1–97.4
91.0–96.0

0.94

Heart disease
With
Without

93.6
94.3

85.5–73.3
91.3–96.2

0.27

Brain stroke
With
Without

92.9
94.4

75.6–98.2
92.0–96.1

0.66

Hypertension
With
Without

96.0
93.2

92.4–97.9
89.9–95.5

0.54

Diabetes mellitus
With
Without

95.5
94.1

86.9–98.5
91.5–95.9

0.69

Smoking
With
Without

97.0
92.7

93.6–98.7
89.4–95.0

0.10

Alcoholic history
With
Without

95.2
93.6

91.7–97.2
90.0–96.0

0.88

	Univariate	Multivariate
Age >75 ≤75	91.2 94.6	80.4–96.3 92.2–96.3	0.78
PS ≤1 >1	94.6 94.2	87.7–97.7 91.6–96.1	0.46
NCCN Low-intermediate risk High risk	90.1 88.6	86.4–93.8 81.3–93.4	0.015	1.05	0.46–2.40	0.90
T stage T1–T2 T3–T4	95.8 86.6	93.4–97.4 78.3–92.0	0.010	1.24	0.56–2.71	0.59
Gleason score ≤8 >8	96.0 84.1	93.7–97.5 74.3–90.6	0.0002	1.52	0.60–3.87	0.35
PSA (ng/ml) ≤50 >50	95.1 77.9	92.9–96.7 58.5–89.8	0.0043	1.24	0.39–3.98	0.72
Radiation therapy PBT IMRT	95.1 89.9	92.7–96.7 80.8–95.0	0.027	2.20	1.13–4.33	0.021
Durations of ADT (month) ≥24 <24	92.7 94.9	87.2–95.9 92.1–96.7	0.45
Nodal risk (%) ≥40 <40	96.1 78.3	94.0–97.6 96.0–87.0	<0.0001	3.87	1.33–11.2	0.013
Private insurance coverage for PBT With coverage Without coverage	94.9 94.0	90.1–97.4 91.0–96.0	0.94
Heart disease With Without	93.6 94.3	85.5–73.3 91.3–96.2	0.27
Brain stroke With Without	92.9 94.4	75.6–98.2 92.0–96.1	0.66
Hypertension With Without	96.0 93.2	92.4–97.9 89.9–95.5	0.54
Diabetes mellitus With Without	95.5 94.1	86.9–98.5 91.5–95.9	0.69
Smoking With Without	97.0 92.7	93.6–98.7 89.4–95.0	0.10
Alcoholic history With Without	95.2 93.6	91.7–97.2 90.0–96.0	0.88

Table 2

Open in new tab

Univariate and multivariate analyses

	Univariate			Multivariate
Parameter	bRFS at 7 years (%)	95% CI	P-value	HR	95% CI	P-value
Age >75 ≤75	91.2 94.6	80.4–96.3 92.2–96.3	0.78
PS ≤1 >1	94.6 94.2	87.7–97.7 91.6–96.1	0.46
NCCN Low-intermediate risk High risk	90.1 88.6	86.4–93.8 81.3–93.4	0.015	1.05	0.46–2.40	0.90
T stage T1–T2 T3–T4	95.8 86.6	93.4–97.4 78.3–92.0	0.010	1.24	0.56–2.71	0.59
Gleason score ≤8 >8	96.0 84.1	93.7–97.5 74.3–90.6	0.0002	1.52	0.60–3.87	0.35
PSA (ng/ml) ≤50 >50	95.1 77.9	92.9–96.7 58.5–89.8	0.0043	1.24	0.39–3.98	0.72
Radiation therapy PBT IMRT	95.1 89.9	92.7–96.7 80.8–95.0	0.027	2.20	1.13–4.33	0.021
Durations of ADT (month) ≥24 <24	92.7 94.9	87.2–95.9 92.1–96.7	0.45
Nodal risk (%) ≥40 <40	96.1 78.3	94.0–97.6 96.0–87.0	<0.0001	3.87	1.33–11.2	0.013
Private insurance coverage for PBT With coverage Without coverage	94.9 94.0	90.1–97.4 91.0–96.0	0.94
Heart disease With Without	93.6 94.3	85.5–73.3 91.3–96.2	0.27
Brain stroke With Without	92.9 94.4	75.6–98.2 92.0–96.1	0.66
Hypertension With Without	96.0 93.2	92.4–97.9 89.9–95.5	0.54
Diabetes mellitus With Without	95.5 94.1	86.9–98.5 91.5–95.9	0.69
Smoking With Without	97.0 92.7	93.6–98.7 89.4–95.0	0.10
Alcoholic history With Without	95.2 93.6	91.7–97.2 90.0–96.0	0.88

	Univariate			Multivariate
Parameter	bRFS at 7 years (%)	95% CI	P-value	HR	95% CI	P-value
Age >75 ≤75	91.2 94.6	80.4–96.3 92.2–96.3	0.78
PS ≤1 >1	94.6 94.2	87.7–97.7 91.6–96.1	0.46
NCCN Low-intermediate risk High risk	90.1 88.6	86.4–93.8 81.3–93.4	0.015	1.05	0.46–2.40	0.90
T stage T1–T2 T3–T4	95.8 86.6	93.4–97.4 78.3–92.0	0.010	1.24	0.56–2.71	0.59
Gleason score ≤8 >8	96.0 84.1	93.7–97.5 74.3–90.6	0.0002	1.52	0.60–3.87	0.35
PSA (ng/ml) ≤50 >50	95.1 77.9	92.9–96.7 58.5–89.8	0.0043	1.24	0.39–3.98	0.72
Radiation therapy PBT IMRT	95.1 89.9	92.7–96.7 80.8–95.0	0.027	2.20	1.13–4.33	0.021
Durations of ADT (month) ≥24 <24	92.7 94.9	87.2–95.9 92.1–96.7	0.45
Nodal risk (%) ≥40 <40	96.1 78.3	94.0–97.6 96.0–87.0	<0.0001	3.87	1.33–11.2	0.013
Private insurance coverage for PBT With coverage Without coverage	94.9 94.0	90.1–97.4 91.0–96.0	0.94
Heart disease With Without	93.6 94.3	85.5–73.3 91.3–96.2	0.27
Brain stroke With Without	92.9 94.4	75.6–98.2 92.0–96.1	0.66
Hypertension With Without	96.0 93.2	92.4–97.9 89.9–95.5	0.54
Diabetes mellitus With Without	95.5 94.1	86.9–98.5 91.5–95.9	0.69
Smoking With Without	97.0 92.7	93.6–98.7 89.4–95.0	0.10
Alcoholic history With Without	95.2 93.6	91.7–97.2 90.0–96.0	0.88

bRFS = biochemical relapse-free survival, NCCN = National Comprehensive Cancer Network, PSA = prostate-specific antigen, PBT = proton beam therapy, IMRT = intensity-modulated radiation therapy, ADT = androgen deprivation therapy

This Feature Is Available To Subscribers Only